Oxford BioMedica PLC Regains Rights to Its Trovax (R) Cancer Vaccine; Will Receive $16.5 Million
Oxford BioMedica’s Chief Executive, John Dawson, said: “We understand and respect that sanofi-aventis’s portfolio review has resulted in a change of focus and a decision not to progress the development of TroVax. We remain committed to the successful development and commercialisation of TroVax and we are working constructively with the FDA to define the potential development path for further trials. Subject to the FDA’s review, we intend to pursue a number of commercial opportunities and, in addition, work with QUASAR and other clinical groups that may want to sponsor independent clinical trials of TroVax.”
John Dawson continued: “We value our relationship with sanofi-aventis and look forward to working with them to achieve the goals of our new partnership in ophthalmology.”